Recent media coverage

Vuoden reseptivalmisteeksi 2013 on valittu Selincro, alkoholinkäytön vähentämiseen tarkoitettu lääke
terve.fi
7 February 2014

Biotie bags option to acquire Neurelis
Pharma Times
7 June 2013

Neurelis, Biotie Therapies enter option and merger agreement
Genetic Engineering & Biotechnology News
4 June 2013

Biotie puts cocaine dependence drug into Phase II
Pharma Times
13 May 2013

Progress Fighting Parkinson's Drug Side Effects
The Wall Street Journal
25 March 2013

Lundbeck gets EU nod for new drug to fight alcohol addiction
FierceBiotech
28 February 2013

UCB licenses global rights to tozadenant in Parkinson's disease from Biotie
The Pharma Letter
27 February 2013

Treatment for alcoholism 'would save thousands'
Pharma Times
12 February 2013

Biotie considers developing Alzheimer’s drug on its own
Bloomberg
21 January 2013

David Cook appointed chief financial officer of Biotie
Pharmafile
7 January 2013

David Cook Named CFO of Biotie
CFO Insight
2 January 2013

CHMP backs Biotie Therapies' Selincro in alcohol dependence
CFO Insight
15 December 2012

Lundbeck's alcohol dependency drug wins EU green light
Reuters
14 December 2012

Lundbeck’s anti-alcoholism pill wins EU regulatory nod
Bloomberg
14 December 2012

Biotie rises most in a year on Parkinson’s trial results
Bloomberg
11 December 2012

Biotie's Parkinson's drug tozadenant clears Phase IIb study
The Pharma Letter
11 December 2012

Study: novel therapy limits 'wearing off' periods associated with Parkinson's drugs
Michael J Fox Foundation – Foxfeed blog
11 December 2012

Lundbeck anti-binge drinking drug helps cut intake by 66%
Bloomberg
5 March 2012

Biotie being courted by potential partners for Alzheimer’s drug
Bloomberg Businessweek
20 February 2012

Panu Miettinen appointed chief financial officer of Biotie
InPharm
16 February 2012

Lundbeck seeks approval for a novel alcoholism treatment
Pharma and Healthcare Insight
30 December 2011

Biotie tests cocaine dependence treatment in USA
Pharma Times
14 December 2011

Scandinavian biotech hit particularly hard in bad year for sector
EPVantage from EvaluatePharma
2 December 2011

Biotie pulls out of merger with Newron
Pharma Times
28 October 2011

Biotie initiates SYN120 Phase 1 study using PET imaging
Medical Devices Business Review
25 July 2011

Lundbeck to file alcoholism pill this year
InPharm
16 June 2011

Lundbeck to file alcoholism drug in Europe by year end
Pharma Times
16 June 2011

Lundbeck finishes alcohol dependency trials
PMLiVE
15 June 2011

Lundbeck nails PhIII for drug to curb alcohol dependence
FierceBiotech
15 June 2011

Nalmefene reaches Phase III endpoints
European Biotechnology News
6 February 2011

Biotie to acquire CNS therapeutics firm Synosia in €93.6M all-shares deal
Genetic Engineering & Biotechnology News
11 January 2011

Biotie buys CNS developer Synosia in $121.5M deal
FierceBiotech
11 January 2011

Alcoholics may stop at one drink with help from Lundbeck anti-abuse drug
Bloomberg
23 December 2010

Päivitetty 10.02.2014